Search Results - "Laria, Luisa Castro"

Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing by Argüelles-Arias, Federico, Valdés Delgado, Teresa, Maldonado Pérez, Belén, González Antuña, Jaime, Castro Laria, Luisa

“…Background: Ustekinumab (UST) is indicated for the treatment of Crohn’s disease (CD) and Ulcerative Colitis (UC). Despite having shown clinical effectiveness…”
Get full text

Carriage of the HLA-DQA1⋆05 haplotype is associated with a higher risk of infratherapeutic drug concentration and higher immunogenicity in patients undergoing treatment with anti-TNF for inflammatory bowel disease by Navajas Hernández, Pilar, Mouhtar El Halabi, Samer, González Parra, Ana Caridad, Valdés Delgado, Teresa, Maldonado Pérez, Belén, Castro Laria, Luisa, Charpentier, Cloé, Argüelles-Arias, Federico

“…The success of anti-tumor necrosis factor (TNF) drug strategies in the treatment of inflammatory bowel disease (IBD) is altered by the development of anti-drug…”
Get full text

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data by Guerra Veloz, María Fernanda, Belvis Jiménez, María, Valdes Delgado, Teresa, Castro Laria, Luisa, Maldonado Pérez, Belén, Perea Amarillo, Raúl, Merino Bohórquez, Vicente, Caunedo Álvarez, Ángel, Vilches Arenas, Ángel, Argüelles-Arias, Federico

“…Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab…”
Get full text

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months by Guerra Veloz, María Fernanda, Vázquez Morón, Juan María, Belvis Jiménez, María, Pallarés Manrique, Héctor, Valdés Delgado, Teresa, Castro Laria, Luisa, Maldonado Pérez, Belén, Benítez Roldán, Antonio, Perea Amarillo, Raúl, Merino, Vicente, Caunedo Álvarez, Ángel, Argüelles Arias, Federico

“…infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of biosimilar treatments such as CT-P13 will hopefully improve the…”
Get full text

A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients by Gómez Rodríguez, Blas José, Castro Laria, Luisa, Argüelles Arias, Federico, Castro Márquez, Cristina, Caunedo Álvarez, Ángel, Romero Gómez, Manuel

“…To evaluate the efficacy and safety of a quadruple regimen (BMTO) of the "3-in-1 capsule" (containing bismuth subcitrate potassium, metronidazole and…”
Get full text

Evolution of the incidence of inflammatory bowel disease in Southern Spain by Chaaro Benallal, Dina, Guerra Veloz, María Fernanda, Argüelles-Arias, Federico, Benítez, José Manuel, Perea Amarillo, Raúl, Iglesias, Eva, Castro Laria, Luisa, Sánchez García, Valle, Maldonado Pérez, María Belen, Vilches, Ángel, Caunedo Álvarez, Ángel, Romero Gómez, Manuel

“…The incidence of inflammatory bowel disease is increasing in Europe and in Spain. However, there is no recent data from Southern Spain. To determine the…”
Get full text

Long-Term Outcomes of Intravenous Ustekinumab Maintenance Treatment in Patients With Loss of Response to Subcutaneous Dosing by Argüelles-Arias, Federico, Rodriguez González, F Javier, González Antuña, Jaime, Castro Laria, Luisa, Gutiérrez Martinez, Fernando, Alcaín Martinez, Guillermo, Maldonado Pérez, Belén, Camargo Camero, Raquel, Martos Van Dussen, J Victor, Fernández Castañer, Alejandra, Valdés Delgado, Teresa

“…Ustekinumab (UST) is commonly used to treat Crohn's disease and ulcerative colitis. However, some patients may experience diminishing response or require…”
Get full text

Retroperitoneal hematoma in Crohn's disease patient with warfarin therapy by Duarte-Chang, Calixto, Castro-Laria, Luisa, Argüelles-Arias, Federico, Caunedo-Álvarez, Ángel, Herrerías Gutiérrez, Juan Manuel

Get full text

Erythema Nodosum: As an Extraintestinal Manifestation or Complication in Ulcerative Colitis? by Valdés Delgado, Teresa, Maldonado Pérez, Belén, Castro Laria, Luisa

“…Abstract In our case, we want to highlight the importance of screening for opportunistic infectious diseases in these immunosuppressed patients. We present the…”
Get full text

Autoimmune Encephalitis During Treatment With Adalimumab: A Case Report in Crohn’s Disease by Fernández Alvarez, Paula, Maldonado Pérez, Belén, Castro Laria, Luisa, Argüelles-Arias, Federico

Get full text

Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results by Argüelles-Arias, Federico, Fernández Álvarez, Paula, Castro Laria, Luisa, Maldonado Pérez, Belén, Belvis Jiménez, María, Merino-Bohórquez, Vicente, Caunedo Álvarez, Ángel, Calleja Hernández, Miguel Ángel

“…A new subcutaneous formulation of the infliximab biosimilar CT-P13 has recently been developed for the treatment of inflammatory bowel disease (IBD), providing…”
Get full text

Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori by Moreno Márquez, Carolina, Fernández Álvarez, Paula, Valdés Delgado, Teresa, Castro Laria, Luisa, Argüelles Arias, Federico, Caunedo Álvarez, Ángel, Gómez Rodríguez, Blas José

“…the primary goal of this study was to compare gastrointestinal symptom reduction in patients on bismuth-containing quadruple eradication therapy supplemented…”
Get full text

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease by Guerra Veloz, María Fernanda, Argüelles-Arias, Federico, Castro Laria, Luisa, Maldonado Pérez, Belén, Benítez Roldan, Antonio, Perea Amarillo, Raúl, Merino Bohórquez, Vicente, Calleja, Miguel Angel, Caunedo Álvarez, Ángel, Vilches Arenas, Ángel

“…Infliximab original has changed the natural history of inflammatory bowel diseases (IBD) over the past two decades. However, the recent expiration of its patent…”
Get full text

Ustekinumab in Crohn's disease: real-world outcomes and predictors of response by Lorenzo González, Laura, Valdés Delgado, Teresa, Vázquez Morón, Juan María, Castro Laria, Luisa, Leo Carnerero, Eduardo, Maldonado Pérez, María Belén, Sánchez Capilla, Damián, Pallarés Manrique, Héctor, Sáez Díaz, Antonia, Argüelles Arias, Federico

“…ustekinumab is a monoclonal antibody that inhibits interleukins IL-12 and IL-23, and is approved for the treatment of Crohn's disease (CD) and, more recently,…”
Get full text

High serum levels of ustekinumab are associated with better clinical outcomes during maintenance treatment for inflammatory bowel disease by González-Antuña, Jaime, Valdés-Delgado, Teresa, Maldonado-Pérez, Belén, Belvis-Jiménez, María, Castro-Laria, Luisa, Merino-Bohórquez, Vicente, Calleja-Hernández, Miguel Ángel, Castro-Martínez, Paula, Charpentier, Cloe, Argüelles-Arias, Federico

“…Ustekinumab (UST) is an effective treatment option in Crohn's disease (CD) and ulcerative colitis (UC). However, it still remains unclear if therapeutic drug…”
Get full text

Vedolizumab response in inflammatory bowel disease. Two years of follow-up by del Pino Bellido, Pilar, Belvis Jiménez, María, Castro Laria, Luisa, Maldonado Pérez, María Belén, Sáez Díaz, Antonia, Caunedo Álvarez, Ángel, Argüelles-Arias, Federico

“…BACKGROUNDvedolizumab is an α4β7 integrin antagonist. The aim of this study was to evaluate the clinical response and remission rates with vedolizumab…”
Get full text

Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practice by Valdés Delgado, Teresa, Guerra Veloz, María Fernanda, Castro Laria, Luisa, Maldonado Pérez, Belén, Perea Amarillo, Raúl, Merino Bohórquez, Vicente, Sáez, Antonia, Caunedo Álvarez, Ángel, Argüelles Arias, Federico

“…between 30 % and 40 % of patients treated with infliximab lose response during maintenance. Therapeutic drug monitoring could be used to optimize management in…”
Get full text

Comparison of the Mayo Endoscopy Score and the Ulcerative Colitis Endoscopy Index of Severity and the Ulcerative Colitis Colonoscopy Index of Severity by Belvis Jiménez, María, Hergueta-Delgado, Pedro, Gómez Rodríguez, Blas, Maldonado Pérez, Belén, Castro Laria, Luisa, Rodríguez-Téllez, Manuel, Morales Barroso, Maria Luisa, Galván Fernández, Maria Dolores, Guerra Veloz, Maria, Jiménez García, Victoria Alejandra, Romero-Castro, Rafael, Benítez-Roladán, Antonio, Castro Márquez, Cristina, Aparcero López, Reyes, Garrido-Serrano, Antonio, Caunedo-Álvarez, Ángel, Argüelles-Arias, Federico

“…Abstract Background and study aims: Endoscopy plays an essential role in managing patients with ulcerative colitis (UC), as it allows us to visualize and…”
Get full text

Initial experience with golimumab in clinical practice for ulcerative colitis by Castro-Laria, Luisa, Argüelles-Arias, Federico, García-Sánchez, Valle, Benítez, José Manuel, Fernández-Pérez, Ramón, Trapero-Fernández, Ana María, Gallardo-Sánchez, Francisco, Pallarés-Manrique, Héctor, Gómez-García, María, Cabello-Tapia, María José, Talavera-Fabuel, Aurora, Bejarano-García, Ana, Leo-Carnerero, Eduardo, Hernández-Martínez, Álvaro, Caunedo-Álvarez, Ángel, Herrerías-Gutiérrez, Juan Manuel

“…Golimumab is a TNF-blocking agent indicated as a second-line therapy in ulcerative colitis. To research the effectiveness and safety of golimumab in patients…”
Get full text

Residual hydrocephalus after tuberculous meningitis in a patient with biological therapy by Márquez, Cristina Castro, Laria, Luisa Castro, Arias, Federico Argüelles, Herrerías, Juan Manuel

Get full text